Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raymond Miller

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
Journal of Pharmacokinetics and Pharmacodynamics|October 3, 2009
Modelling overdispersion and Markovian features in count dataIñaki F Trocóniz, Elodie L Plan, Raymond Miller, et al.
Journal of Pharmacokinetics and Pharmacodynamics|May 1, 2012
Analysis of exposure-response of CI-945 in patients with epilepsy: application of novel mixed hidden Markov modeling methodologyMaud Delattre, Radojka M Savic, Raymond Miller, et al.
Journal of Pharmacokinetics and Pharmacodynamics|February 24, 2004
A two-part mixture model for longitudinal adverse event severity dataKenneth G Kowalski, Lynn McFadyen, Matthew M Hutmacher, et al.
Clinical Pharmacokinetics|September 8, 2010
A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentinHoward N Bockbrader, David Wesche, Raymond Miller, et al.
Journal of Agricultural and Food Chemistry|February 16, 2006
Modified 2,2-azino-bis-3-ethylbenzothiazoline-6-sulfonic acid (abts) method to measure antioxidant capacity of Selected small fruits and comparison to ferric reducing antioxidant power (FRAP) and 2,2'-diphenyl-1-picrylhydrazyl (DPPH) methodsMustafa Ozgen, R Neil Reese, Artemio Z Tulio, et al.
Clinical Pharmacology and Therapeutics|June 18, 2003
Exposure-response analysis of pregabalin add-on treatment of patients with refractory partial seizuresRaymond Miller, Bill Frame, Brian Corrigan, et al.
Journal of Clinical Pharmacology|October 1, 2010
ACoP: the tools, carpenters, and architects building the discipline of pharmacometricsRichard C Brundage, Marc Pfister, David Z D'Argenio, et al.
Urology|December 20, 2005
Highly specific urine-based marker of bladder cancerThu-Suong Van Le, Raymond Miller, Timothy Barder, et al.
Journal of Clinical Pharmacology|October 1, 2010
Defining the future of pharmacometrics: the American Society of PharmacometricsMarc Pfister, Richard C Brundage, Marc R Gastonguay, et al.
Journal of Pharmacokinetics and Pharmacodynamics|January 6, 2012
Affiliation between the American Society of Pharmacometrics and the Journal of Pharmacokinetics and PharmacodynamicsDavid Z D'Argenio, Marc R Gastonguay, Richard C Brundage, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Journal of Pharmacokinetics and Pharmacodynamics|October 3, 2009
Modelling overdispersion and Markovian features in count dataIñaki F Trocóniz, Elodie L Plan, Raymond Miller, et al.
Journal of Pharmacokinetics and Pharmacodynamics|May 1, 2012
Analysis of exposure-response of CI-945 in patients with epilepsy: application of novel mixed hidden Markov modeling methodologyMaud Delattre, Radojka M Savic, Raymond Miller, et al.
Journal of Pharmacokinetics and Pharmacodynamics|February 24, 2004
A two-part mixture model for longitudinal adverse event severity dataKenneth G Kowalski, Lynn McFadyen, Matthew M Hutmacher, et al.
Clinical Pharmacokinetics|September 8, 2010
A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentinHoward N Bockbrader, David Wesche, Raymond Miller, et al.
Journal of Agricultural and Food Chemistry|February 16, 2006
Modified 2,2-azino-bis-3-ethylbenzothiazoline-6-sulfonic acid (abts) method to measure antioxidant capacity of Selected small fruits and comparison to ferric reducing antioxidant power (FRAP) and 2,2'-diphenyl-1-picrylhydrazyl (DPPH) methodsMustafa Ozgen, R Neil Reese, Artemio Z Tulio, et al.
Clinical Pharmacology and Therapeutics|June 18, 2003
Exposure-response analysis of pregabalin add-on treatment of patients with refractory partial seizuresRaymond Miller, Bill Frame, Brian Corrigan, et al.
Journal of Clinical Pharmacology|October 1, 2010
ACoP: the tools, carpenters, and architects building the discipline of pharmacometricsRichard C Brundage, Marc Pfister, David Z D'Argenio, et al.
Urology|December 20, 2005
Highly specific urine-based marker of bladder cancerThu-Suong Van Le, Raymond Miller, Timothy Barder, et al.
Journal of Clinical Pharmacology|October 1, 2010
Defining the future of pharmacometrics: the American Society of PharmacometricsMarc Pfister, Richard C Brundage, Marc R Gastonguay, et al.
Journal of Pharmacokinetics and Pharmacodynamics|January 6, 2012
Affiliation between the American Society of Pharmacometrics and the Journal of Pharmacokinetics and PharmacodynamicsDavid Z D'Argenio, Marc R Gastonguay, Richard C Brundage, et al.
Pageof 5